查看文章

Background: There are no established risk factors or toxicity biomarkers for ECs and GCs treated with ICI, even though they are commonly used in current clinical practice. Additionally, the predictive value of programmed death-ligand 1 (PDL1) expression level is questionable. This is a retrospective review of patients with EC or GC treated with ICI at an academic institute to identify RF for poor outcomes. Methods: Patients with EC or GC who received at least one dose of ICI for Stage IV or recurrent disease between 1/1/2015 and 7/31/2021 at the Ohio State University were included in the study. The patients' baseline (BL) characteristics (at the first dose of ICI) were extracted with immune-related adverse events (irAE) details and survival outcomes. Descriptive statistics, Fisher exact test for categorical variables, log-rank test for survival outcomes, and logistic regression modeling for categorical outcomes were …